Valid 1 March 2004
SUBSTANCES AND METHODS
PROHIBITED IN-COMPETITION
S1. STIMULANTS
The following stimulants are prohibited, including both their optical (D- and L-) isomers
where relevant:
Adrafinil, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, bromantan, carphedon, cathine*, clobenzorex, cocaine, dimethylamphetamine, ephedrine**, etilamphetamine, etilefrine, fencamfamin,
fenetylline, fenfluramine, fenproporex, furfenorex, mefenorex, mephentermine, mesocarb, methamphetamine, methylamphetamine, methylenedioxyamphetamine, methylenedioxymethamphetamine, methylephedrine**, methylphenidate, modafinil, nikethamide, norfenfluramine, parahydroxyamphetamine, pemoline, phendimetrazine, phenmetrazine, phentermine, prolintane, selegiline, strychnine and other substances with similar chemical structure or similar pharmacological effect(s)***.
* Cathine is prohibited when its concentration in urine is greater than 5 micrograms per millilitre.
** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per millilitre.
*** The substances included in the 2004 Monitoring Program are not considered as prohibited substances.
S2. NARCOTICS
The following narcotics are prohibited:
buprenorphine, dextromoramide, diamorphine (heroin), hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.
S3. CANNABINOIDS
Cannabinoids (e.g. hashish, marijuana) are prohibited.
S4. ANABOLIC AGENTS
Anabolic agents are prohibited.
1. Anabolic Androgenic Steroids (AAS)
a. Exogenous* AAS including, but not limited to:
androstadienone, bolasterone, boldenone, boldione, clostebol, danazol, dehydrochloromethyltestosterone, delta1-androstene-3,17-dione, drostanolone, drostanediol, fluoxymesterone, formebolone, gestrinone, 4-hydroxytestosterone, 4-hydroxy-19-nortestosterone, mestanolone, mesterolone, methandienone,
metenolone, methandriol, methyltestosterone, mibolerone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, norbolethone, norethandrolone, oxabolone, oxandrolone, oxymesterone, oxymetholone, quinbolone, stanozolol, stenbolone, 1-testosterone (delta1-dihydro-testosterone), trenbolone and other substances with similar chemical structure or similar pharmacological effect(s).
b. Endogenous** AAS, including but not limited to:
androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone, testosterone and other substances with similar chemical structure or similar pharmacological effect(s).
Where a prohibited substance (as listed above) is capable of being produced by the body naturally, a sample will be deemed to contain such prohibited substance where the concentration of the prohibited substance or its metabolites or markers and/or any other relevant ratio(s) in the athlete�s sample so deviates from the range of values normally found in humans so as not to be consistent with normal endogenous production. A sample shall not be deemed to contain a prohibited substance in any such case where the athlete proves by clear and convincing evidence that the concentration of the prohibited substance or its metabolites or markers and/or the relevant ratio(s) in the athlete�s sample is attributable to a pathological or physiological condition. In all cases, and at any concentration, the laboratory will report an adverse analytical finding if, based on any reliable analytical method, it can show that the prohibited substance is of exogenous origin.
If the laboratory result is not conclusive and no concentration as referred to in the above paragraph is found, a further investigation shall be conducted, such as a comparison to reference steroid profiles, for a possible use of a prohibited substance.
If the laboratory has reported the presence of a T/E ratio greater than six (6) to one (1) in the urine, further investigation is obligatory in order to determine whether the ratio is due to a physiological or pathological condition.
In both cases, the investigation will include a review of any previous tests, subsequent tests and/or results of endocrine investigations. If previous tests are not available, the athlete shall undergo an endocrine investigation or be tested unannounced at least three times within a three month period.
Failure of the athlete to co-operate in the investigations will result in considering the athlete�s sample to contain a prohibited substance.
2. Other Anabolic Agents
Clenbuterol, zeranol.
For purposes of this section:
* �exogenous� refers to a substance which is not capable of being produced by the body naturally.
** �endogenous� refers to a substance which is capable of being produced by the body naturally.
S5. PEPTIDE HORMONES
The following substances, including other substances with similar chemical structure or
similar pharmacological effect(s), and their releasing factors, are prohibited:
1. Erythropoietin (rh-EPO);
2. Growth hormone (hGH) and Insulin-like Growth Factor (IGF-1);
3. Chorionic Gonadotrophin (hCG) prohibited in males only;
4. Pituitary and synthetic gonadotrophins (LH) prohibited in males only;
5. Insulin;
6. Corticotrophins.
Unless the athlete can demonstrate that the concentration was due to a physiological or pathological condition, a sample will be deemed to contain a prohibited substance (as listed above) where the concentration of the prohibited substance or its metabolites and/or relevant ratios or markers in the athlete�s sample so exceeds the range of values normally found in humans so as not to be consistent with normal endogenous production.
The presence of other substances with similar chemical structure or similar pharmacological effect(s), diagnostic marker(s) or releasing factors of a hormone listed above, or of any other finding which indicate(s) that the substance detected is not the naturally present hormone, will be reported as an adverse analytical finding.
S6. BETA-2 AGONISTS
All beta-2 agonists including their D- and L- isomers are prohibited except that formoterol, salbutamol, salmeterol and terbutaline are permitted by inhalation only to prevent and/or treat asthma and exercise-induced asthma/broncho-constriction. A TUE in accordance with Chapter 5 of the 2004 IAAF Procedural Guidelines for Doping Control is required.
Despite the granting of a TUE, when the laboratory has reported a concentration of
salbutamol (free plus glucuronide) greater than 1000 ng/mL, this will be considered as an
adverse analytical finding unless the athlete proves that the abnormal result was the
consequence of the therapeutic use of inhaled salbutamol.
S7. AGENTS WITH ANTI-OESTROGENIC ACTIVITY
Aromatase inhibitors, clomiphene, cyclofenil, tamoxifen are prohibited only in males.
S8. MASKING AGENTS
Masking agents are prohibited. They are products that have the potential to impair the excretion of prohibited substances, to conceal their presence in urine or other samples used in doping control, or to change haematological parameters.
Masking agents include but are not limited to:
Diuretics*, epitestosterone, probenecid, plasma expanders (e.g. dextran, hydroxyethyl starch.)
*A TUE is not valid if an athlete�s urine contains a diuretic in association with threshold
or sub-threshold levels of a prohibited substance(s).
Diuretics include:
acetazolamide, amiloride, bumetanide, canrenone, chlortalidone, etacrynic acid, furosemide, indapamide, mersalyl, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene and other substances with similar chemical structure or similar pharmacological effect(s).
S.9 GLUCOCORTICOSTEROIDS
Glucocorticosteroids are prohibited when administered orally, rectally, or by intravenous or intramuscular administration.
All other administration routes require a TUE in accordance with Chapter 5.24 of the 2004 IAAF Procedural Guidelines for Doping Control.
PROHIBITED METHODS
M1. ENHANCEMENT OF OXYGEN TRANSFER
The following are prohibited:
a. Blood doping. Blood doping is the use of autologous, homologous or heterologous blood or red blood cell products of any origin, other than for legitimate medical treatment.
b. The use of products that enhance the uptake, transport or delivery of oxygen, e.g. recombinant erythropoietins, modified haemoglobin products including but not limited to haemoglobin-based blood substitutes, microencapsulated haemoglobin products, perfluorochemicals, and efaproxiral (RSR13).
M2. PHARMACOLOGICAL, CHEMICAL AND PHYSICAL MANIPULATION
Pharmacological, chemical and physical manipulation is the use of substances and methods, including masking agents, which alter, attempt to alter or may reasonably be expected to alter the integrity and validity of specimens collected in doping controls. These include but are not limited to catheterisation, urine substitution and/or tampering, inhibition of renal excretion and alterations of testosterone and epitestosterone concentrations.
M3. GENE DOPING
Gene or cell doping is defined as the non-therapeutic use of genes, genetic elements and/or cells that have the capacity to enhance athletic performance.
SUBSTANCES AND METHODS
PROHIBITED IN- AND OUT-OF-COMPETITION
PROHIBITED SUBSTANCES
(All categories listed hereunder refer to all those prohibited substances and methods listed
in the relevant section)
S4. ANABOLIC AGENTS
S5. PEPTIDE HORMONES
S6. BETA-2 AGONISTS*
S7. AGENTS WITH ANTI-OESTROGENIC ACTIVITY
S8. MASKING AGENTS
(*Only clenbuterol, and salbutamol when its concentration in urine is greater than
1000ng/mL)
PROHIBITED METHODS
M1. ENHANCEMENT OF OXYGEN TRANSFER
M2. PHARMACOLOGICAL, CHEMICAL AND PHYSICAL MANIPULATION
M3. GENE DOPING
SPECIFIED SUBSTANCES
�Specified Substances� are listed below:
Stimulants: ephedrine, L-methylamphetamine, methylephedrine;
Cannabinoids;
Inhaled Beta-2 Agonists (except clenbuterol);
Diuretics;
Masking Agents: probenecid;
Glucocorticosteroids.
